Baudax Bio, Inc.
BXRX · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $0 | $0 |
| % Growth | 17.5% | 119.1% | – | – |
| Cost of Goods Sold | $7 | $2 | $2 | $0 |
| Gross Profit | -$6 | -$1 | -$1 | $0 |
| % Margin | -452.3% | -126.4% | -251.3% | – |
| R&D Expenses | $6 | $3 | $9 | $20 |
| G&A Expenses | $15 | $0 | $0 | $27 |
| SG&A Expenses | $24 | $45 | $43 | $27 |
| Sales & Mktg Exp. | $9 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $3 | $2 | -$0 |
| Operating Expenses | $30 | $51 | $55 | $47 |
| Operating Income | -$36 | -$19 | -$75 | -$33 |
| % Margin | -2,816.6% | -1,759.8% | -15,169.6% | – |
| Other Income/Exp. Net | -$23 | $33 | -$1 | $7 |
| Pre-Tax Income | -$59 | -$20 | -$76 | -$33 |
| Tax Expense | $0 | $0 | $0 | -$15 |
| Net Income | -$59 | -$20 | -$76 | -$18 |
| % Margin | -4,633.2% | -1,830.5% | -15,436.1% | – |
| EPS | -177.3 | -361.16 | -5,715.36 | -2,695.87 |
| % Growth | 50.9% | 93.7% | -112% | – |
| EPS Diluted | -177.3 | -361.16 | -5,715.36 | -2,695.87 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1 | $0 |
| Interest Expense | $21 | $2 | $1 | $0 |
| Depreciation & Amortization | $2 | -$29 | $22 | -$29 |
| EBITDA | -$36 | -$48 | -$75 | -$39 |
| % Margin | -2,803.6% | -4,468.5% | -15,169.6% | – |